CIK 0001061983 · Large accelerated filer
CYTOKINETICS INC
Sign in to watch- Ticker
- CYTK
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 943291317
- Phone
- (650) 624-3000
- Business address
- 350 OYSTER POINT BOULEVARD, ., SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,208,275
- in 16 filings, $12.2M under 10b5-1 plans
Net −$12,208,275. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-21 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −2,000 | 37,105 | ||
| 2025-01-07 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +2,000 | $10.60 | $21K | 118,071 |
| 2025-01-07 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −2,000 | $49.32 | $99K | 116,071 |
| 2025-01-07 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −2,000 | 39,105 | ||
| 2025-01-02 | HENDERSON JOHN T Director | Grant or award | +434 | $48.93 | $21K | 48,987 |
| 2025-01-02 | Harrington Robert Arthur Director | Grant or award | +255 | $48.93 | $12K | 16,008 |
| 2025-01-02 | Kaye Edward M. MD Director | Grant or award | +255 | $48.93 | $12K | 25,637 |
| 2025-01-02 | Wysenski Nancy Director | Grant or award | +127 | $48.93 | $6K | 23,115 |
| 2025-01-02 | WIERENGA WENDALL Director | Grant or award | +127 | $48.93 | $6K | 24,686 |
| 2024-12-16 | WIERENGA WENDALL Director | Option exercise 10b5-1 | +742 | $7.37 | $5K | 25,301 |
| 2024-12-16 | WIERENGA WENDALL Director | Sale 10b5-1 | −742 | $48.61 | $36K | 24,559 |
| 2024-12-16 | WIERENGA WENDALL Director | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −742 | 0 | ||
| 2024-12-11 | HENDERSON JOHN T Director | Option exercise 10b5-1 | +1,780 | $7.37 | $13K | 40,241 |
| 2024-12-11 | HENDERSON JOHN T Director | Sale 10b5-1 | −1,780 | $50.42 | $90K | 38,461 |
| 2024-12-11 | HENDERSON JOHN T Director | Option exercise 10b5-1 | +10,092 | $7.37 | $74K | 48,553 |
| 2024-12-11 | HENDERSON JOHN T Director | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −1,780 | 10,092 | ||
| 2024-12-11 | HENDERSON JOHN T Director | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −10,092 | 0 | ||
| 2024-12-10 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +5,300 | $7.96 | $42K | 123,371 |
| 2024-12-10 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −5,300 | $50.63 | $268K | 118,071 |
| 2024-12-10 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −2,000 | $50.65 | $101K | 116,071 |
Page 24 of 33 · 660 trades